Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 287

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 287
---
’s income tax expense to the Company’s theoretical statutory tax benefit is as follows:

|                                                                                        |     | Year Ended December 31, |  2023 |   |     |   |  2022 |   |
|:---------------------------------------------------------------------------------------|:----|:------------------------|------:|:--|:----|:--|------:|:--|
| Loss before taxes on income                                                            |     | $                       | 4,132 |   |     | $ | 1,449 |   |
| Israeli statutory income tax rate                                                      |     |                         |  23.0 | % |     |   |  23.0 | % |
| Theoretical statutory tax benefit                                                      |     |                         |   950 |   |     |   |   333 |   |
| Revaluation of convertible notes                                                       |     |                         |  (464 | ) |     |   |   (91 | ) |
| Temporary deductible difference                                                        |     |                         |   (26 | ) |     |   |   (94 | ) |
| Losses for which a valuation allowance was provided or benefit from loss carryforwards 
 and permanent differences                                                              |     |                         |  (460 | ) |     |   |  (148 | ) |
| Income tax expense                                                                     |     | $                       |     - |   |     | $ |     - |   |

<div align='center'>F-36</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004 and December                                                                       
 2015, the Company received funding from the IIA for its participation in certain research and development 
 activities, based on budgets approved by the IIA, subject to the fulfillment of specified milestones.     
 The Company is committed to pay royalties to the IIA on proceeds from sale of products related to         
 research and development activities of which the IIA participates by way of grants. According to          
 the funding terms, royalties between 3% and 4.5% are payable on sales of developed products funded,       
 up to 100% of the grant received by the Company, linked to U.S. dollar and bearing Term SOFR interest     
 rate. In the case of failure of a funded research and development activity, the Company is not obligated  
 to pay